Premium
Real‐world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in E ast A sia
Author(s) -
Hong Jihyung,
Novick Diego,
Montgomery William,
Moneta Maria Victoria,
Dueñas Héctor,
Peng Xiaomei,
Haro Josep Maria
Publication year - 2016
Publication title -
asia‐pacific psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 21
eISSN - 1758-5872
pISSN - 1758-5864
DOI - 10.1111/appy.12178
Subject(s) - duloxetine , duloxetine hydrochloride , medicine , odds ratio , major depressive disorder , serotonin reuptake inhibitor , reuptake inhibitor , depression (economics) , post hoc analysis , quality of life (healthcare) , subgroup analysis , antidepressant , mood , meta analysis , psychiatry , alternative medicine , nursing , macroeconomics , pathology , hippocampus , economics
This study compared treatment outcomes in patients with major depressive disorder treated with either duloxetine with a daily dose of ≤60 mg or a selective serotonin reuptake inhibitor ( SSRI ) as monotherapy for up to 6 months in a naturalistic setting in E ast A sia. In addition, this study examined the impact of painful physical symptoms ( PPS ) on the effects of these treatments. Methods This post‐hoc analysis of data from a 6‐month prospective observational study involving 1,549 major depressive disorder patients without sexual dysfunction focused on a subgroup of patients from E ast A sia ( n = 587). Depression severity was measured using the C linical G lobal I mpression of S everity and the 16‐item Q uick I nventory of D epressive S ymptomatology S elf‐ R eport ( QIDS ‐ SR 16 ), whereas quality of life ( QoL ) was measured using E uro QoL instruments. PPS were rated using the modified S omatic S ymptom I nventory. Multiple regression analyses were performed to compare the treatment outcomes. Results Duloxetine‐treated patients had higher odds of achieving remission (odds ratio = 2.578, P < 0.001) and response (odds ratio = 2.704, P < 0.001) during follow‐up, compared with SSRI ‐treated patients. They also had lower levels of disease severity and higher levels of QoL during follow‐up. A similar pattern was observed in each subgroup of patients with and without PPS at baseline, but the effects of duloxetine relative to SSRIs were in general greater in patients with PPS . Discussion Patients treated with duloxetine had better treatment outcomes in terms of remission, response, depressive symptoms, and QoL , compared with SSRIs . Treatment with duloxetine may have additional advantages for patients with concurrent PPS .